Bioequivalence Study of Fenofibric Acid Versus Tricor® (Fenofibrate)
Status:
Completed
Trial end date:
2007-11-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the bioequivalence of 105 mg fenofibric acid tablets relative to 145
mg fenofibrate tablets in healthy volunteers under fasting conditions. A secondary objective
is to characterize the pharmacokinetic profile of fenofibric acid when administered as a
single 105 mg dose to healthy volunteers in a fasted state. Safety and tolerability of this
regimen will also be evaluated.